196 related articles for article (PubMed ID: 30971541)
1. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions.
Sadullahoğlu C; Sayıner A; Süren D; Yıldırım HT; Nergiz D; Sezer C; Oruç MT
Indian J Pathol Microbiol; 2019; 62(2):206-210. PubMed ID: 30971541
[TBL] [Abstract][Full Text] [Related]
2. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
3. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
4. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
5. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
6. A Bedside Risk Calculator to Preoperatively Distinguish Follicular Thyroid Carcinoma from Follicular Variant of Papillary Thyroid Carcinoma.
Englum BR; Pura J; Reed SD; Roman SA; Sosa JA; Scheri RP
World J Surg; 2015 Dec; 39(12):2928-34. PubMed ID: 26324158
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
8. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
9. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
10. Important cytological findings for distinction between follicular variant and conventional papillary thyroid carcinoma, including noninvasive follicular thyroid tumors with papillary-like nuclear features.
Koshikawa T; Fujita N; Ueda N; Ota Y; Sasaki E; Murakami Y; Hosoda W; Yatabe Y; Hanai N; Higuchi M; Hirokawa M; Miyauchi A
Endocr J; 2019 May; 66(5):475-483. PubMed ID: 30867345
[TBL] [Abstract][Full Text] [Related]
11. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
12. [Thyrocyte morphomethric analysis significance in differential diagnosis of thyroid carcinoma].
Janković SK; Andjelković Z; Cerović S; Milosavljević I
Vojnosanit Pregl; 2011 Aug; 68(8):669-75. PubMed ID: 21991790
[TBL] [Abstract][Full Text] [Related]
13. The Role of Claudin-1 Expression in Follicular and Papillary Thyroid Neoplasm.
Miskad UA; Aswidah A; Dahlan H; Ikram D; Cangara MH; Djimahit T; Kaelan C
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4023-4027. PubMed ID: 36579982
[TBL] [Abstract][Full Text] [Related]
14. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
16. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
17. EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers.
Gao X; Zhang R; He Y; Wang X; Bao W; Feng X; Chai J; Wang J
Ann Diagn Pathol; 2024 Apr; 69():152262. PubMed ID: 38150866
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
19. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
20. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions.
Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M
Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
